Literature DB >> 21417562

Use of the levonorgestrel releasing-intrauterine system in nulliparous women--a non-interventional study in Sweden.

Lena Marions1, Lena Lövkvist, Annika Taube, Monica Johansson, Håkan Dalvik, Inger Øverlie.   

Abstract

OBJECTIVES: To evaluate the insertion procedure and continuation rates of the levonorgestrel releasing-intrauterine system (LNG-IUS) in nulliparous women who, due to fear of complications, are often denied this very effective contraceptive method.
METHODS: A non-interventional study of 224 nulliparous women attending family planning services for insertion of a LNG-IUS.
RESULTS: There were only six unsuccessful insertions. The insertions, mostly carried out by midwives, were regarded as easy by 72% of the inserters. Nineteen women (9%) considered the procedure to have been painless, 162 (72%) moderately painful, and 39 (17%), severely painful. At follow-up, 12-16 weeks post-insertion, 76% (165/216) of the women were satisfied with their method. Women in the youngest age group were more satisfied than women in the oldest age group (75% and 59%, respectively). Only 5% were dissatisfied. Neither perforations nor pregnancies were reported during the whole study period.
CONCLUSION: Our results support the current practice in Sweden of offering LNG-IUS routinely to nulliparous women.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21417562     DOI: 10.3109/13625187.2011.558222

Source DB:  PubMed          Journal:  Eur J Contracept Reprod Health Care        ISSN: 1362-5187            Impact factor:   1.848


  11 in total

1.  Objective Assessment of Cervical Stiffness after Administration of Misoprostol for Intrauterine Contraceptive Insertion.

Authors:  S Badir; E Mazza; M Bajka
Journal:  Ultrasound Int Open       Date:  2016-05-03

2.  Precision intrauterine contraception may significantly increase continuation of use: a review of long-term clinical experience with frameless copper-releasing intrauterine contraception devices.

Authors:  Dirk Wildemeersch; Ansgar Pett; Sohela Jandi; Thomas Hasskamp; Patrick Rowe; Marc Vrijens
Journal:  Int J Womens Health       Date:  2013-04-30

3.  Levonorgestrel intrauterine system (Mirena): An emerging tool for conservative treatment of abnormal uterine bleeding.

Authors:  Pallavi C Dhamangaonkar; K Anuradha; Archana Saxena
Journal:  J Midlife Health       Date:  2015 Jan-Mar

Review 4.  Practical advice for avoidance of pain associated with insertion of intrauterine contraceptives.

Authors:  Luis Bahamondes; Diana Mansour; Christian Fiala; Andrew M Kaunitz; Kristina Gemzell-Danielsson
Journal:  J Fam Plann Reprod Health Care       Date:  2013-09-27

5.  Experience and levels of satisfaction with the levonorgestrel-releasing intrauterine system in China: a prospective multicenter survey.

Authors:  Shuping Zhao; Jihong Deng; Yan Wang; Shiliang Bi; Xiaoye Wang; Wen Qin; Zirong Huang; Li Li; Xin Mi; Liping Han; Qing Chang; Jian Li
Journal:  Patient Prefer Adherence       Date:  2014-10-23       Impact factor: 2.711

6.  Intrauterine contraception in nulliparous women: a prospective survey.

Authors:  Alexandra M Hall; Beth A Kutler
Journal:  J Fam Plann Reprod Health Care       Date:  2015-04-08

Review 7.  Benefits of reversible contraception.

Authors:  Helena Kopp Kallner
Journal:  F1000Res       Date:  2018-06-29

8.  Early versus delayed insertion of intrauterine contraception after medical abortion - a randomized controlled trial.

Authors:  Ingrid Sääv; Olof Stephansson; Kristina Gemzell-Danielsson
Journal:  PLoS One       Date:  2012-11-14       Impact factor: 3.240

Review 9.  Management of pain associated with the insertion of intrauterine contraceptives.

Authors:  K Gemzell-Danielsson; D Mansour; C Fiala; A M Kaunitz; L Bahamondes
Journal:  Hum Reprod Update       Date:  2013-05-12       Impact factor: 15.610

Review 10.  A review of barriers and myths preventing the more widespread use of intrauterine contraception in nulliparous women.

Authors:  Kirsten Black; Pamela Lotke; Kai J Buhling; Nikki B Zite
Journal:  Eur J Contracept Reprod Health Care       Date:  2012-07-26       Impact factor: 1.848

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.